Bayer has added another phase 3 trial into its registration program for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,